DDIT3 and prostate carcinoma: Priming prostate cancer cells with ONC201 for 24 h followed by radiation, maintained the over-expression of both signatures at 72 h (PERK/CHOP plus IRE1a/ATF6) (Fig. 2e; Supplementary Fig. 2a—right side and c).